BioCorRx

BICX

Medical - Care Facilities · Healthcare

Price

$0.29

-0.01 (-2.00%)

Market Cap

$6.1M

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+184.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 6.5M (2021) → 18.5M (2025)

BioCorRx Inc. is a small healthcare company focused on treating addiction, mainly alcohol and opioid dependence. Its core product is the BICX treatment program, which combines a naltrexone implant — a small device placed under the skin that blocks the effects of opioids and alcohol — with counseling support. The company sells its treatment through licensed healthcare providers and addiction treatment clinics across the United States.

BioCorRx earns revenue by licensing its treatment protocol to providers and through product sales related to its implant technology. It is a very small company with a market cap near zero, meaning it has limited financial resources compared to larger pharmaceutical or addiction treatment firms. The high gross margin suggests the core product carries decent pricing power, but the deeply negative operating margin shows the company is spending far more than it earns, which is the central risk — it must raise additional capital or significantly grow revenue to remain a going concern.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+59.0% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

+46.1% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$2M/ year

↑ Rising (+19% vs prior year)

221.9% of revenue

12.3x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

66.6%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~1 months

$211,911 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Strong grower

BioCorRx is growing revenue at 59% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

0.0%

Thin — 0.0% gross margin

Operating Margin

-445.6%

Losing money on operations — -445.6%

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+531.1%

Fast-growing sales (531.1% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

-232.8%

Burning cash (-232.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial